Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 3:7:56.
doi: 10.3389/fonc.2017.00056. eCollection 2017.

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers

Benjamin L Maughan  1   2 , Erin Bailey  1 , David M Gill  2 , Neeraj Agarwal  1   2
Affiliations
Review

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers

Benjamin L Maughan et al. Front Oncol. .

Abstract

Program death receptor-1 (PD-1) and program death receptor-1 ligand (PD-L1) inhibitors are increasingly being used in the clinic to treat a growing number of malignancies, including many genitourinary (GU) malignancies. These immune-based therapies have demonstrated a distinct toxicity profile compared to traditional chemotherapy and the targeted therapies directed at the vascular endothelial growth factor pathway or the mammalian target of rapamycin pathway. Autoimmune toxicity targeting the skin, gastrointestinal tract, or the endocrine organs are some of the more common adverse events (AEs) noted with these therapies. Here in, we report the results of a systematic review of the incidence of toxicities in GU cancers reported in the phase II or phase III clinical trials using single-agent PD-1 or PD-L1 inhibitors. Overall, the rate of serious (grades 3-4) AEs was noted in approximately 15% of patients. The AEs noted were similar between all the agents tested, highlighting the overall class effect of these therapies. The incidence in GU cancers is similar to those seen in other malignancies. Given the widespread and high volume real-world use of these agents, it is important for oncologists to be familiar with these side effects to minimize the risks for patients while undergoing therapy.

Keywords: autoimmune; checkpoint blockade; immune-related adverse events; immunotherapy; toxicity; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PD-1/PD-L1 mechanism of action. Key: MHC, major histocompatibility; APC, antigen presenting cell; PD-L1, programmed death ligand-1; PD-1, programmed death receptor-1; TCR, T-cell receptor.
Figure 2
Figure 2
Data selection process (18).
See this image and copyright information in PMC

References

    1. Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2015) 7(6):365–77.10.1177/1756287215597647 - DOI - PMC - PubMed
    1. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol (2015) 23:32–8.10.1016/j.coph.2015.05.011 - DOI - PMC - PubMed
    1. Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol (2015) 68(2):267–79.10.1016/j.eururo.2015.02.032 - DOI - PubMed
    1. Bracarda S, Altavilla A, Hamzaj A, Sisani M, Marrocolo F, Del Buono S, et al. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. Semin Oncol (2015) 42(3):495–505.10.1053/j.seminoncol.2015.02.004 - DOI - PubMed
    1. Tsiatas M, Grivas P. Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med (2016) 4(14):270.10.21037/atm.2016.06.29 - DOI - PMC - PubMed